はしか、おたふくかぜ、風疹ワクチン市場- 世界の産業規模、シェア、動向、機会、予測、種類別、対象人口別、流通チャネル別、地域別、競合別、2020-2030年

はしか、おたふくかぜ、風疹（MMR）ワクチンの世界市場は、2024年に18億7,000万米ドルと評価され、予測期間中にCAGR 8.42％で成長し、2030年には30億4,000万米ドルに達すると予測されています。

市場成長の原動力となっているのは、基本的な公衆衛生対策としての予防接種需要の増加です。WHOやユニセフのような国際機関からの支援に後押しされ、国の予防接種スケジュールにMMRワクチンが組み込まれたことで、高所得国でも低所得国でも広く採用されるようになりました。麻疹の再発は、特に十分なサービスを受けていない人々において顕著であり、大規模な予防接種キャンペーンの必要性を浮き彫りにしています。ヘルスケアインフラの強化、官民パートナーシップ、流通ロジスティクスの改善により、ワクチンへのアクセスと接種率はさらに向上しています。

市場概要
予測期間	2026-2030
市場規模：2024年	18億7,000万米ドル
市場規模：2030年	30億4,000万米ドル
CAGR：2025年～2030年	8.42%
急成長セグメント	小児科および民間ヘルスケアクリニック
最大市場	北米

耐熱性製剤や針を使わない製剤など、ワクチン投与方法の革新も、特に資源に制約のある環境での成長を後押ししています。MMRを他の小児用ワクチンと組み合わせて1回接種にする動向は、予防接種スケジュールを簡素化し、アドヒアランスを向上させています。デジタル医療システムとの統合は、接種率やフォローアップの追跡に役立ち、プログラムの効率を高めています。

市場促進要因

政府による予防接種イニシアチブの増加

主な市場課題

ワクチン嫌いと誤った情報

主要市場動向

普遍的予防接種プログラムへのMMRワクチンの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（一価、三価（MMR併用）、四価）
  • 対象者別（乳幼児（9ヶ月～12歳）、成人）
  • 流通チャネル別（病院およびヘルスケア機関、ワクチンセンターおよび公衆衛生診療所、小児科および民間ヘルスケア診療所）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米のはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのはしか、おたふくかぜ、風疹ワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Measles, Mumps, and Rubella (MMR) Vaccine Market was valued at USD 1.87 billion in 2024 and is projected to reach USD 3.04 billion by 2030, growing at a CAGR of 8.42% during the forecast period. Market growth is being fueled by increasing demand for immunization as a fundamental public health measure. The inclusion of MMR vaccines in national immunization schedules, bolstered by support from international agencies such as WHO and UNICEF, has led to widespread adoption in both high- and low-income countries. Recurring outbreaks of measles, especially in underserved populations, highlight the need for large-scale vaccination campaigns. Strengthening healthcare infrastructure, public-private partnerships, and improved distribution logistics are further enhancing vaccine access and coverage.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.87 Billion
Market Size 2030	USD 3.04 Billion
CAGR 2025-2030	8.42%
Fastest Growing Segment	Pediatric and Private Healthcare Clinics
Largest Market	North America

Innovation in vaccine delivery methods, including thermostable and needle-free formulations, is also driving growth, particularly in resource-constrained settings. The trend of combining MMR with other pediatric vaccines into a single-dose format is simplifying immunization schedules and improving adherence. Integration with digital health systems is aiding in tracking vaccination coverage and follow-ups, enhancing program efficiency.

Key Market Drivers

Increasing Government Immunization Initiatives

Government-led immunization initiatives have become a pivotal factor driving the global MMR vaccine market. Countries worldwide are prioritizing vaccine-preventable disease control by integrating MMR into routine childhood immunization programs, often at no cost. Increased funding, improved logistics, and targeted rural outreach are elevating vaccine coverage. Supported by organizations such as WHO, UNICEF, and Gavi, these initiatives are reducing disease incidence and mortality, particularly in low-income nations.

Despite such efforts, global immunization coverage still falls short of WHO's 95% target needed for measles elimination. In 2023, only 83% of children globally received the first measles vaccine dose, while just 74% received the second. Alarmingly, over 22 million children missed their first dose. These figures underline the urgency for governments to scale up immunization efforts through enhanced policies, monitoring, and education, reinforcing sustained demand for MMR vaccines.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, driven by misinformation and distrust, remains a substantial barrier to broader adoption of MMR vaccines. Persistent myths, such as a link between the MMR vaccine and autism, continue to undermine public confidence despite being scientifically disproven. The proliferation of false information via social media and other platforms exacerbates hesitancy, particularly in communities with limited access to reliable healthcare education.

These attitudes delay or reduce vaccine uptake, leading to disease resurgence and undermining public health goals. Overcoming this issue requires coordinated efforts involving community leaders, healthcare providers, and policymakers to promote accurate information and build trust. Tailored education campaigns and transparent communication strategies will be key to addressing misinformation and improving vaccine acceptance across regions.

Key Market Trends

Integration of MMR Vaccines into Universal Immunization Programs

The increasing integration of MMR vaccines into universal immunization programs is a notable trend supporting market expansion. Governments, with backing from global health bodies, are embedding MMR vaccination within broader public health strategies to improve childhood immunization coverage. These efforts are essential in achieving herd immunity and controlling disease outbreaks.

According to WHO, global measles vaccine coverage remains insufficient, with only 83% of children receiving the first dose and 74% the second in 2023. Nearly 35 million children lacked full protection against measles. These gaps emphasize the need for inclusive immunization strategies. As countries intensify efforts to close these coverage gaps, the demand for reliable MMR vaccines is expected to grow significantly.

Key Market Players

• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Panacea Biotec Ltd.
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Biological E. Limited
• Emergent BioSolutions Inc.

Report Scope

In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Measles, Mumps, Rubella Vaccine Market, By Type:

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

Measles, Mumps, Rubella Vaccine Market, By Targeted Population:

• Infants and Children (9 months to 12 years)
• Adults

Measles, Mumps, Rubella Vaccine Market, By Distribution Channel:

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric and Private Healthcare Clinics

Measles, Mumps, Rubella Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Measles, Mumps, Rubella Vaccine Market.

Available Customizations

Global Measles, Mumps, Rubella Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Measles, Mumps, Rubella Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Monovalent, Trivalent (combined MMR), Tetravalent)
  • 5.2.2. By Targeted Population (Infants and children (9 months to 12), Adults)
  • 5.2.3. By Distribution Channel (Hospitals and Healthcare Institutions, Vaccine Centers and Public Health Clinics, Pediatric and Private Healthcare Clinics)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Measles, Mumps, Rubella Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Targeted Population
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Targeted Population
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Targeted Population
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Measles, Mumps, Rubella Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Targeted Population
      • 6.3.3.2.3. By Distribution Channel

7. Europe Measles, Mumps, Rubella Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Targeted Population
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Targeted Population
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Targeted Population
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Targeted Population
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Targeted Population
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Measles, Mumps, Rubella Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Targeted Population
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Measles, Mumps, Rubella Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Targeted Population
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Targeted Population
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Targeted Population
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Targeted Population
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Targeted Population
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Measles, Mumps, Rubella Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Targeted Population
      • 8.3.5.2.3. By Distribution Channel

9. South America Measles, Mumps, Rubella Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Targeted Population
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Targeted Population
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Targeted Population
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Measles, Mumps, Rubella Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Targeted Population
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Measles, Mumps, Rubella Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Targeted Population
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Targeted Population
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Targeted Population
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Measles, Mumps, Rubella Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Targeted Population
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. GlaxoSmithKline plc
• 14.3. Pfizer Inc.
• 14.4. Novartis AG
• 14.5. Serum Institute of India Pvt. Ltd.
• 14.6. Panacea Biotec Ltd.
• 14.7. Takeda Pharmaceutical Company Limited
• 14.8. Sinovac Biotech Ltd.
• 14.9. Biological E. Limited
• 14.10. Emergent BioSolutions Inc.

15. Strategic Recommendations

16. About Us & Disclaimer